Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Smith

Showing results (151-160 of 168) with videos related to

Pageof 17
Sort By:
European Urology|March 18, 2014
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohortEthan Basch, Karen A Autio, Matthew R Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion studyMatthew R Smith, Christopher J Sweeney, Paul G Corn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2023
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.
Journal for Immunotherapy of Cancer|June 29, 2023
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomasAndrew L Coveler, David C Smith, Tycel Phillips, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 6, 2019
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in OncologyTimothy Gilligan, Daniel W Lin, Rahul Aggarwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2017
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012Maha Hussain, Stephanie Daignault-Newton, Przemyslaw W Twardowski, et al.
Science Translational Medicine|December 3, 2011
Personalized oncology through integrative high-throughput sequencing: a pilot studySameek Roychowdhury, Matthew K Iyer, Dan R Robinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2021
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate CancerSamuel R Denmeade, Hao Wang, Neeraj Agarwal, et al.
JAMA Oncology|February 25, 2021
Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid TumorsErin F Cobain, Yi-Mi Wu, Pankaj Vats, et al.
Pageof 17

Showing results (151-160 of 168) with videos related to

Sort By:
Pageof 17
European Urology|March 18, 2014
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohortEthan Basch, Karen A Autio, Matthew R Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion studyMatthew R Smith, Christopher J Sweeney, Paul G Corn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2023
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabSuzanne L Topalian, Mario Sznol, David F McDermott, et al.
Journal for Immunotherapy of Cancer|June 29, 2023
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomasAndrew L Coveler, David C Smith, Tycel Phillips, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|December 6, 2019
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in OncologyTimothy Gilligan, Daniel W Lin, Rahul Aggarwal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 21, 2017
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012Maha Hussain, Stephanie Daignault-Newton, Przemyslaw W Twardowski, et al.
Science Translational Medicine|December 3, 2011
Personalized oncology through integrative high-throughput sequencing: a pilot studySameek Roychowdhury, Matthew K Iyer, Dan R Robinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2021
TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate CancerSamuel R Denmeade, Hao Wang, Neeraj Agarwal, et al.
JAMA Oncology|February 25, 2021
Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid TumorsErin F Cobain, Yi-Mi Wu, Pankaj Vats, et al.
Pageof 17